Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer

Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer treatment options can be adjusted by panel ne...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arlou Kristina Angeles, Florian Janke, Simone Bauer, Petros Christopoulos, Anja Lisa Riediger, Holger Sültmann
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	liquid biopsy cell-free DNA precision medicine fragmentomics epigenomics DNA methylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0c924f9ef37f4d23a92f3dd9f8e7b175
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c924f9ef37f4d23a92f3dd9f8e7b175
record_format	dspace
spelling	oai:doaj.org-article:0c924f9ef37f4d23a92f3dd9f8e7b1752021-11-25T17:01:38ZLiquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer10.3390/cancers132256152072-6694https://doaj.org/article/0c924f9ef37f4d23a92f3dd9f8e7b1752021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5615https://doaj.org/toc/2072-6694Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer treatment options can be adjusted by panel next-generation sequencing (NGS)-based evaluation of driver mutations in cfDNA, emerging research additionally explores the value of deep characterization of tumor cfDNA genomics and fragmentomics as well as nucleosome modifications (chromatin structure), and methylation patterns (epigenomics) for comprehensive and multi-modal assessment of cfDNA. These tools have the potential to improve disease monitoring, increase the sensitivity of minimal residual disease identification, and detection of cancers at earlier stages. Recent progress in emerging technologies of cfDNA analysis is summarized, the added potential clinical value is highlighted, strengths and limitations are identified and compared with conventional targeted NGS analysis, and current challenges and future directions are discussed.Arlou Kristina AngelesFlorian JankeSimone BauerPetros ChristopoulosAnja Lisa RiedigerHolger SültmannMDPI AGarticleliquid biopsycell-free DNAprecision medicinefragmentomicsepigenomicsDNA methylationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5615, p 5615 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liquid biopsy cell-free DNA precision medicine fragmentomics epigenomics DNA methylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	liquid biopsy cell-free DNA precision medicine fragmentomics epigenomics DNA methylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Arlou Kristina Angeles Florian Janke Simone Bauer Petros Christopoulos Anja Lisa Riediger Holger Sültmann Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
description	Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer treatment options can be adjusted by panel next-generation sequencing (NGS)-based evaluation of driver mutations in cfDNA, emerging research additionally explores the value of deep characterization of tumor cfDNA genomics and fragmentomics as well as nucleosome modifications (chromatin structure), and methylation patterns (epigenomics) for comprehensive and multi-modal assessment of cfDNA. These tools have the potential to improve disease monitoring, increase the sensitivity of minimal residual disease identification, and detection of cancers at earlier stages. Recent progress in emerging technologies of cfDNA analysis is summarized, the added potential clinical value is highlighted, strengths and limitations are identified and compared with conventional targeted NGS analysis, and current challenges and future directions are discussed.
format	article
author	Arlou Kristina Angeles Florian Janke Simone Bauer Petros Christopoulos Anja Lisa Riediger Holger Sültmann
author_facet	Arlou Kristina Angeles Florian Janke Simone Bauer Petros Christopoulos Anja Lisa Riediger Holger Sültmann
author_sort	Arlou Kristina Angeles
title	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
title_short	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
title_full	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
title_fullStr	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
title_full_unstemmed	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
title_sort	liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free dna in cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0c924f9ef37f4d23a92f3dd9f8e7b175
work_keys_str_mv	AT arloukristinaangeles liquidbiopsiesbeyondmutationcallinggenomicandepigenomicfeaturesofcellfreednaincancer AT florianjanke liquidbiopsiesbeyondmutationcallinggenomicandepigenomicfeaturesofcellfreednaincancer AT simonebauer liquidbiopsiesbeyondmutationcallinggenomicandepigenomicfeaturesofcellfreednaincancer AT petroschristopoulos liquidbiopsiesbeyondmutationcallinggenomicandepigenomicfeaturesofcellfreednaincancer AT anjalisariediger liquidbiopsiesbeyondmutationcallinggenomicandepigenomicfeaturesofcellfreednaincancer AT holgersultmann liquidbiopsiesbeyondmutationcallinggenomicandepigenomicfeaturesofcellfreednaincancer
_version_	1718412756555661312

Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer

Ejemplares similares